Response to first-line treatment
Treatment group . | Complete remission, n (%) . | Remission duration, median (range), mo . | Relapse rate, n (%) of CR patients . | HCT, n (%) of CR patients . |
---|---|---|---|---|
AML-like (n = 19) | 13 (68.4) | 68 (4-399)* | 4 (28.5) | 7 (2 auto) (36.8-53.8) |
ALL-like (n = 19) | 15 (78.9) | 47 (6-224) | 5 (33.3) | 7 (46.7) |
Aspa-MTX (n = 16) | 12 (75) | 26 (5-166) | 4 (33.3) | 6 (37.5-50) |
CHOP-like (n = 16) | 6 (37.5) | 17 (4-22)* | 4 (66.7) | 2 (12.5-33.3) |
NOS (n = 10) | 1 | 35 | 0 | 0 |
Treatment group . | Complete remission, n (%) . | Remission duration, median (range), mo . | Relapse rate, n (%) of CR patients . | HCT, n (%) of CR patients . |
---|---|---|---|---|
AML-like (n = 19) | 13 (68.4) | 68 (4-399)* | 4 (28.5) | 7 (2 auto) (36.8-53.8) |
ALL-like (n = 19) | 15 (78.9) | 47 (6-224) | 5 (33.3) | 7 (46.7) |
Aspa-MTX (n = 16) | 12 (75) | 26 (5-166) | 4 (33.3) | 6 (37.5-50) |
CHOP-like (n = 16) | 6 (37.5) | 17 (4-22)* | 4 (66.7) | 2 (12.5-33.3) |
NOS (n = 10) | 1 | 35 | 0 | 0 |
Data are missing for 1 patient.